|
PY0111577A
(es)
|
2000-05-23 |
2017-01-02 |
Idenix Cayman Ltd |
Métodos y composiciones para el tratamiento del virus de la hepatitis c
|
|
RU2005118421A
(ru)
|
2002-11-15 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
2'-разветвленные нуклеозиды и мутация flaviviridae
|
|
BRPI0419345B8
(pt)
|
2003-05-30 |
2021-05-25 |
Gilead Pharmasset Llc |
uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
|
|
MX2007003085A
(es)
*
|
2004-09-14 |
2007-08-02 |
Pharmasset Inc |
Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
|
|
WO2006055193A1
(en)
|
2004-11-16 |
2006-05-26 |
Thomson Licensing |
Film grain simulation method based on pre-computed transform coefficients
|
|
KR101229942B1
(ko)
|
2004-11-16 |
2013-02-06 |
톰슨 라이센싱 |
비디오 시스템에서 비트까지 정확한 시뮬레이션을 위한필름 그레인 sei 메시지 삽입
|
|
ZA200703946B
(en)
|
2004-11-17 |
2008-08-27 |
Thomson Licensing |
Bit-accurate film grain simulation method based on pre-computed transformed coefficients
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
US10715834B2
(en)
|
2007-05-10 |
2020-07-14 |
Interdigital Vc Holdings, Inc. |
Film grain simulation based on pre-computed transform coefficients
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
JP6104504B2
(ja)
|
2008-12-23 |
2017-03-29 |
ギリアド ファーマセット エルエルシー |
ヌクレオシド類似体
|
|
CL2009002206A1
(es)
*
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
|
TW201026715A
(en)
|
2008-12-23 |
2010-07-16 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
UY33312A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidato de nucleosido de purina
|
|
CL2011000716A1
(es)
|
2010-03-31 |
2012-04-20 |
Gilead Pharmasset Llc |
Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
|
|
JP5716500B2
(ja)
*
|
2010-06-03 |
2015-05-13 |
セントラル硝子株式会社 |
(2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類前駆体の製造方法
|
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
|
CN103842369A
(zh)
|
2011-03-31 |
2014-06-04 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
SI2709613T2
(sl)
|
2011-09-16 |
2020-12-31 |
Gilead Pharmasset LLC c/o Gilead Sciences, Inc. |
Postopki za zdravljenje HCV
|
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
CN104023726A
(zh)
|
2011-10-21 |
2014-09-03 |
艾伯维公司 |
用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
|
|
CA2811203C
(en)
|
2011-10-21 |
2015-05-05 |
Abbvie Inc. |
Methods for treating hcv
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
|
HUE029038T2
(en)
|
2012-05-25 |
2017-01-30 |
Janssen Sciences Ireland Uc |
Uracil spirooxetan nucleosides
|
|
AU2013269799A1
(en)
|
2012-05-29 |
2014-10-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of 2-deoxy-2-fluoro-2-methyl-D-ribofuranosyl nucleoside compounds
|
|
CN103450148B
(zh)
*
|
2012-06-04 |
2018-06-12 |
浙江九洲药业股份有限公司 |
一种五元环硫酸酯化合物的合成方法
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
SG11201502750UA
(en)
|
2012-10-08 |
2015-06-29 |
Idenix Pharmaceuticals Inc |
2'-chloro nucleoside analogs for hcv infection
|
|
CN103724301A
(zh)
|
2012-10-10 |
2014-04-16 |
上海特化医药科技有限公司 |
(2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
|
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CN103012386B
(zh)
*
|
2012-12-26 |
2015-04-01 |
浙江普洛得邦制药有限公司 |
一种五元环状硫酸酯的制备方法
|
|
NZ729172A
(en)
|
2013-01-31 |
2018-06-29 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
|
US10034893B2
(en)
|
2013-02-01 |
2018-07-31 |
Enanta Pharmaceuticals, Inc. |
5, 6-D2 uridine nucleoside/tide derivatives
|
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
EP2970357B1
(en)
|
2013-03-13 |
2025-01-01 |
Idenix Pharmaceuticals LLC |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
JP2016529293A
(ja)
|
2013-08-27 |
2016-09-23 |
ギリアド ファーマセット エルエルシー |
2つの抗ウイルス化合物の組合せ製剤
|
|
CN104447923B
(zh)
*
|
2013-09-23 |
2018-03-30 |
中国药科大学 |
2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
US9675632B2
(en)
|
2014-08-26 |
2017-06-13 |
Enanta Pharmaceuticals, Inc. |
Nucleoside and nucleotide derivatives
|
|
WO2016042576A1
(en)
|
2014-09-16 |
2016-03-24 |
Cadila Healthcare Limited |
Co-crystal of sofosbuvir and amino acid and process for preparation thereof
|
|
CN104744539A
(zh)
*
|
2014-09-19 |
2015-07-01 |
上海皓元生物医药科技有限公司 |
一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的合成方法
|
|
CN104327138B
(zh)
*
|
2014-10-21 |
2017-05-10 |
齐鲁制药有限公司 |
Psi‑7977中间体化合物的制备方法
|
|
US9718851B2
(en)
|
2014-11-06 |
2017-08-01 |
Enanta Pharmaceuticals, Inc. |
Deuterated nucleoside/tide derivatives
|
|
US9732110B2
(en)
|
2014-12-05 |
2017-08-15 |
Enanta Pharmaceuticals, Inc. |
Nucleoside and nucleotide derivatives
|
|
CN104610404B
(zh)
*
|
2015-01-16 |
2016-04-06 |
南通常佑药业科技有限公司 |
一种呋喃核糖磷酸酯衍生物的制备方法
|
|
GEP20217282B
(en)
|
2015-03-06 |
2021-08-10 |
Atea Pharmaceuticals Inc |
β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
|
|
CN104829672B
(zh)
*
|
2015-05-19 |
2018-03-13 |
江苏福瑞生物医药有限公司 |
一种药物中间体的合成方法
|
|
CN105061535A
(zh)
*
|
2015-09-02 |
2015-11-18 |
江苏科本医药化学有限公司 |
一种索非布韦中间体的合成方法
|
|
CN106554333B
(zh)
*
|
2015-09-29 |
2018-11-30 |
江苏福瑞生物医药有限公司 |
一种药物中间体的合成方法
|
|
CN106608896B
(zh)
*
|
2015-10-26 |
2019-08-27 |
江苏福瑞康泰药业有限公司 |
一种药物中间体的合成方法
|
|
CN105418547A
(zh)
*
|
2015-11-17 |
2016-03-23 |
海门慧聚药业有限公司 |
索非布韦关键中间体的制备
|
|
CN105503983B
(zh)
*
|
2015-12-17 |
2019-06-28 |
江苏阿尔法药业有限公司 |
索菲布韦中间体及其衍生物的制备方法
|
|
CN105566422B
(zh)
*
|
2015-12-29 |
2019-06-25 |
江苏阿尔法药业有限公司 |
索菲布韦中间体或其衍生物的制备方法
|
|
JP7129703B2
(ja)
|
2016-04-28 |
2022-09-02 |
エモリー ユニバーシティー |
アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
|
|
WO2018013937A1
(en)
|
2016-07-14 |
2018-01-18 |
Atea Pharmaceuticals, Inc. |
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
US10239910B2
(en)
|
2016-07-20 |
2019-03-26 |
Optimus Drugs (P) Limited |
Process for the preparation of sofosbuvir
|
|
PT3512863T
(pt)
|
2016-09-07 |
2022-03-09 |
Atea Pharmaceuticals Inc |
Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
|
|
CN110248951B
(zh)
|
2017-02-01 |
2022-10-28 |
阿堤亚制药公司 |
用于治疗丙型肝炎病毒的核苷酸半硫酸盐
|
|
CN106810515A
(zh)
*
|
2017-02-06 |
2017-06-09 |
抚州市星辰药业有限公司 |
一种合成索非布韦的中间体化合物及其合成方法
|
|
CN109422789A
(zh)
*
|
2017-08-28 |
2019-03-05 |
常州制药厂有限公司 |
一种索非布韦的制备工艺改进方法
|
|
WO2019200005A1
(en)
|
2018-04-10 |
2019-10-17 |
Atea Pharmaceuticals, Inc. |
Treatment of hcv infected patients with cirrhosis
|
|
CN108675984A
(zh)
*
|
2018-06-22 |
2018-10-19 |
江苏阿尔法药业有限公司 |
索非布韦中间体的制备方法
|
|
CN111606961A
(zh)
*
|
2019-02-26 |
2020-09-01 |
顾世海 |
一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的工艺生产方法
|
|
CN111040010A
(zh)
*
|
2019-12-23 |
2020-04-21 |
上海红蓝医药科技有限公司 |
一种索非布韦中间体的合成方法
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
BR112023026356A2
(pt)
|
2021-06-17 |
2024-03-05 |
Atea Pharmaceuticals Inc |
Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
|